Nature de la demande
Radiation
Arrêt du remboursement suite à un arrêt de commercialisation.
Avis favorable à l’arrêt du remboursement de la spécialité IMBRUVICA (ibrutinib) 140 mg, gélule dans les indications de l’AMM.
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
Dmtv7LamgKZwaWg1
